Pfizer, Bristol-Myers Squibb, and Roche are advancing cancer therapies focusing on EMT, with Pfizer's PF-06952229 and BMS-986416 targeting TGF-β to inhibit metastasis. Propanc Biopharma's PRP is a dual-action proenzyme therapy that can reverse EMT and eliminate cancer stem cells, showing an extension of survival by 3.4 months in compassionate use studies. PRP holds 90 patents and plans to initiate Phase I clinical trials in 2026 aimed at preventing the recurrence and resistance of various cancers.

EMT-0.09%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)